ArticleJournal of substance abuse treatment2021
Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.
Article in Journal of substance abuse treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Long-Acting Injectable Buprenorphine in Prison: Insights From a Short-Answer Survey of People in the Criminal Justice System Commencing Long-Acting Injectable Buprenorphine During a Non-Randomised Clinical Trial.Drug and alcohol review · 2026Article
- Article
- "You'll come in and dose even in a global pandemic": A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic.The International journal on drug policy · 2023Article
- Substance use disorders and COVID-19: reflections on international research and practice changes during the "poly-crisis".Frontiers in public health · 2023Article
- Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?European addiction research · 2023Article
- Disparities in naloxone prescriptions in a University Hospital during the COVID-19 pandemic.Harm reduction journal · 2022Article
- Heterogeneity of the COVID-19 epidemic: what can we learn from it?American journal of translational research · 2022Review
- Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations.World journal of psychiatry · 2021Review
- Maintaining treatment and prevention programs for opioid use disorders during the coronavirus disease 2019 pandemic.Current opinion in psychiatry · 2021Review
- Provider Perceptions Toward Extended-Release Buprenorphine for Treatment of Opioid Use Disorder.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.